These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1337164)

  • 1. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients.
    Lui SF; Ali AA; Grundy JE; Fernando ON; Griffiths PD; Sweny P
    Nephrol Dial Transplant; 1992; 7(12):1230-7. PubMed ID: 1337164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients.
    Hirsch MS; Schooley RT; Cosimi AB; Russell PS; Delmonico FL; Tolkoff-Rubin NE; Herrin JT; Cantell K; Farrell ML; Rota TR; Rubin RH
    N Engl J Med; 1983 Jun; 308(25):1489-93. PubMed ID: 6304513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.
    Ishida JH; Patel A; Mehta AK; Gatault P; McBride JM; Burgess T; Derby MA; Snydman DR; Emu B; Feierbach B; Fouts AE; Maia M; Deng R; Rosenberger CM; Gennaro LA; Striano NS; Liao XC; Tavel JA
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection.
    Metselaar HJ; Rothbarth PH; Brouwer RM; Wenting GJ; Jeekel J; Weimar W
    Transplantation; 1989 Aug; 48(2):264-6. PubMed ID: 2547256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.
    Brayman KL; Dafoe DC; Smythe WR; Barker CF; Perloff LJ; Naji A; Fox IJ; Grossman RA; Jorkasky DK; Starr SE
    Arch Surg; 1988 Dec; 123(12):1502-8. PubMed ID: 2847687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
    N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
    Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
    Lee YM; Kim YH; Han DJ; Park SK; Park JS; Sung H; Hong HL; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Lee SO
    Transpl Infect Dis; 2014 Jun; 16(3):397-402. PubMed ID: 24810355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.